{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:22:00Z","timestamp":1784312520438,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Influenza antiviral stockpiling represents a critical component of pandemic preparedness, yet evolving challenges demand new approaches to this strategic imperative. The Strategic National Stockpile\u2019s target of maintaining antiviral courses for 25% of the United States population reflects both economic modeling and practical experience from recent pandemics, including the 2009 influenza A(H1N1) and coronavirus disease-19 pandemics. This perspective examines the evolution of antiviral stockpiling strategies, highlighting key lessons from these events as well as challenges in supply chain resilience, resistance management, and rapid deployment. The increasing diversity of available antivirals, from traditional neuraminidase inhibitors to a newer cap-dependent endonuclease inhibitor and emerging host-targeted therapeutics, offers opportunities for more robust stockpiling strategies. However, this diversity also introduces complexities in decision-making, storage, and deployment. Recent advances in artificial intelligence and manufacturing technologies present promising solutions for enhancing stockpile management, potentially enabling more responsive just-in-time production capabilities. The integration of rapid diagnostics, streamlined distribution systems, and novel therapeutic approaches could transform traditional stockpiling paradigms. This analysis provides a framework for optimizing antiviral stockpiles that balances immediate pandemic response capabilities with long-term strategic considerations, while addressing critical challenges in resistance management, pediatric formulations, and supply chain resilience.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf264","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T02:27:06Z","timestamp":1760668026000},"page":"S309-S313","source":"Crossref","is-referenced-by-count":5,"title":["Optimizing Antiviral Stockpiles for Pandemic Response: A Strategic Framework"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2879-2612","authenticated-orcid":false,"given":"Rick A","family":"Bright","sequence":"first","affiliation":[{"name":"Bright Global Health , Waterford, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101622265694900_jiaf264-B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 influenza: the mother of all pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2025101622265694900_jiaf264-B2","author":"US Department of Health and Human Services"},{"key":"2025101622265694900_jiaf264-B3","first-page":"2234","article-title":"Influenza stockpiling and health-system effectiveness: a simulation model for pandemic preparedness","volume":"366","author":"Balicer","year":"2005","journal-title":"Lancet"},{"key":"2025101622265694900_jiaf264-B4","first-page":"S177","article-title":"Use of influenza antivirals in pandemic response","volume":"232","author":"Zambon","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jinf.2011.06.008","article-title":"Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan","volume":"63","author":"Sugaya","year":"2011","journal-title":"J Infect"},{"key":"2025101622265694900_jiaf264-B6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025101622265694900_jiaf264-B7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101622265694900_jiaf264-B8","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B9","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1093\/infdis\/jiaf116","article-title":"Use of influenza antivirals to prevent transmission","volume":"232","author":"Cowling","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B10","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1093\/infdis\/jiaf126","article-title":"New developments in influenza polymerase inhibitors","volume":"232","author":"Li","year":"2025","journal-title":"J InfectDis"},{"key":"2025101622265694900_jiaf264-B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015\u20132016","volume":"146","author":"Gubareva","year":"2017","journal-title":"Antiviral Res"},{"key":"2025101622265694900_jiaf264-B12","doi-asserted-by":"crossref","first-page":"1900170","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalized child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"key":"2025101622265694900_jiaf264-B13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"2025101622265694900_jiaf264-B14","first-page":"S273","article-title":"Laboratory Methods for Monitoring Influenza Antiviral Resistance","volume":"232","author":"Takashita","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025101622265694900_jiaf264-B16","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1093\/infdis\/jiaf218","article-title":"Point-of-Care and Home Use Influenza Diagnostics for Advancing Therapeutic and Public Health Strategies","volume":"232","author":"Damhorst","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B17","doi-asserted-by":"crossref","first-page":"105499","DOI":"10.1016\/j.antiviral.2022.105499","article-title":"Influenza antivirals and their role in pandemic preparedness","volume":"210","author":"Jones","year":"2023","journal-title":"Antiviral Res"},{"key":"2025101622265694900_jiaf264-B18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00018-025-05611-1","article-title":"Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches","volume":"82","author":"Bonomini","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"2025101622265694900_jiaf264-B19","first-page":"S262","article-title":"Host Immunomodulatory Interventions in Severe Influenza","volume":"232","author":"Hui","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B20","first-page":"S254","article-title":"Platform trials to assess therapeutics in patients hospitalized with influenza","volume":"232","author":"Waite","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B21","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1056\/NEJMoa0908482","article-title":"Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks","volume":"362","author":"Lee","year":"2010","journal-title":"N Engl J Med"},{"key":"2025101622265694900_jiaf264-B22","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1093\/infdis\/jiaf258","article-title":"Influenza Antiviral Pharmacokinetic-Pharmacodynamic Relationships in Pregnancy, Infancy, and Early Childhood","volume":"232","author":"Hastings","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101622265694900_jiaf264-B23","doi-asserted-by":"crossref","first-page":"e16094","DOI":"10.1371\/journal.pone.0016094","article-title":"Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza","volume":"6","author":"Dimitrov","year":"2011","journal-title":"PLoS One"},{"key":"2025101622265694900_jiaf264-B24","author":"Biomedical Advanced Research and Development Authority"},{"key":"2025101622265694900_jiaf264-B25","author":"US Food and Drug Administration"},{"key":"2025101622265694900_jiaf264-B26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrd.2017.232","article-title":"Automating drug discovery","volume":"17","author":"Schneider","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025101622265694900_jiaf264-B27","doi-asserted-by":"crossref","first-page":"eaax1566","DOI":"10.1126\/science.aax1566","article-title":"A robotic platform for flow synthesis of organic compounds informed by AI planning","volume":"365","author":"Coley","year":"2019","journal-title":"Science"},{"key":"2025101622265694900_jiaf264-B28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A deep learning approach to antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_3\/S309\/64720094\/jiaf264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_3\/S309\/64720094\/jiaf264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T02:27:10Z","timestamp":1760668030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/Supplement_3\/S309\/8287897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":28,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf264","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,10,15]]}}}